BIOMAT Database Logo BIOMAT Database Logo

Amphotericin B for visceral leishmaniasis resistant to pentavalent antimonial drugs in AIDS. 1994

F Rodilla, and J Magraner, and J Aznar, and F Orovitg, and F Alcácer, and J Colomina, and F Ferriols

UI MeSH Term Description Entries
D007898 Leishmaniasis, Visceral A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African. Black Fever,Kala-Azar,Fever, Black,Kala Azar,Visceral Leishmaniasis
D008297 Male Males
D008536 Meglumine 1-Deoxy-1-(methylamino)-D-glucitol. A derivative of sorbitol in which the hydroxyl group in position 1 is replaced by a methylamino group. Often used in conjunction with iodinated organic compounds as contrast medium. Methylglucamine
D009942 Organometallic Compounds A class of compounds of the type R-M, where a C atom is joined directly to any other element except H, C, N, O, F, Cl, Br, I, or At. (Grant & Hackh's Chemical Dictionary, 5th ed) Metallo-Organic Compound,Metallo-Organic Compounds,Metalloorganic Compound,Organometallic Compound,Metalloorganic Compounds,Compound, Metallo-Organic,Compound, Metalloorganic,Compound, Organometallic,Compounds, Metallo-Organic,Compounds, Metalloorganic,Compounds, Organometallic,Metallo Organic Compound,Metallo Organic Compounds
D010419 Pentamidine Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. Pentamidine Isethionate,Diamidine,Lomidine,NebuPent,Pentacarinat,Pentam,Pentamidin,Pentamidine Mesylate
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077485 Meglumine Antimoniate ANTIMONY salt of meglumine that is used in the treatment of LEISHMANIASIS. Glucantime,N-Methylglucamine Antimonate,N Methylglucamine Antimonate
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

F Rodilla, and J Magraner, and J Aznar, and F Orovitg, and F Alcácer, and J Colomina, and F Ferriols
Amphotericin B in resistant visceral leishmaniasis.
June 1996, Indian pediatrics,
F Rodilla, and J Magraner, and J Aznar, and F Orovitg, and F Alcácer, and J Colomina, and F Ferriols
Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
January 2005, International journal of antimicrobial agents,
F Rodilla, and J Magraner, and J Aznar, and F Orovitg, and F Alcácer, and J Colomina, and F Ferriols
Liposomal amphotericin B in drug-resistant visceral leishmaniasis.
May 1991, Lancet (London, England),
F Rodilla, and J Magraner, and J Aznar, and F Orovitg, and F Alcácer, and J Colomina, and F Ferriols
Amphotericin B formulations and other drugs for visceral leishmaniasis.
March 2015, The American journal of tropical medicine and hygiene,
F Rodilla, and J Magraner, and J Aznar, and F Orovitg, and F Alcácer, and J Colomina, and F Ferriols
Pentavalent antimonial treatment in mucosal leishmaniasis.
May 1985, Lancet (London, England),
F Rodilla, and J Magraner, and J Aznar, and F Orovitg, and F Alcácer, and J Colomina, and F Ferriols
Renal function improvement with pentavalent antimonial agents in patients with visceral leishmaniasis.
January 2011, American journal of nephrology,
F Rodilla, and J Magraner, and J Aznar, and F Orovitg, and F Alcácer, and J Colomina, and F Ferriols
[Visceral leishmaniasis resistant to conventional treatments: value of amphotericin B].
October 1993, Pathologie-biologie,
F Rodilla, and J Magraner, and J Aznar, and F Orovitg, and F Alcácer, and J Colomina, and F Ferriols
Cutaneous sporotrichoid leishmaniasis resistant to pentavalent antimonial therapy: complete resolution with itraconazole.
January 2011, Clinical and experimental dermatology,
F Rodilla, and J Magraner, and J Aznar, and F Orovitg, and F Alcácer, and J Colomina, and F Ferriols
Amphotericin B in visceral leishmaniasis.
November 1996, Indian pediatrics,
F Rodilla, and J Magraner, and J Aznar, and F Orovitg, and F Alcácer, and J Colomina, and F Ferriols
Amphotericin B in visceral leishmaniasis.
January 1993, Indian pediatrics,
Copied contents to your clipboard!